EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR

Minle Li, Xuan Chen, Pengfei Qu, Zhiying Shao, Lei Shi, Haoyu Quan, Xue Zhao, Jian Xu, Luling Shi, Silu Chen, Junnian Zheng, Zhen-Qiang Pan und 1 weitere

Proceedings of the National Academy of Sciences · 2024

DOI: 10.1073/pnas.2402035121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Minle Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Colorectal Neoplasms, Colitis, F-Box Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD) is a considerable threat to human health with a significant risk for colorectal cancer (CRC). However, currently, both the molecular pathogenesis and therapeutic treatment of IBD remain limited. In this report, using both systemic and intestinal epithelium-specific gene knockout mouse models, we demonstrate that FBXO22, a substrate receptor within the SKP1-Cullin 1-F-box family of E3 ubiquitin ligases, plays an inhibitory role in the Azoxymethane / Dextran Sodium Sulfate–induced colorectal inflammatory responses and CRC. FBXO22 targets the serine 2448-phosphorylated form of mammalian mechanistic target of rapamycin (pS2448-mTOR) for ubiquitin-dependent degradation. This proteolytic targeting effect is established based on multiple lines of evidence including the results of colon tissue immunoblots, analysis of cultured cells with altered abundance of FBXO22 by depletion or overexpression, comparison of protein decay rate, effects on mTOR substrates S6K1 and 4E-BP1, analysis of protein–protein interactions, phosphor–peptide binding and competition, as well as reconstituted and cellular ubiquitination. Finally, we have shown that mTOR inhibitor rapamycin (RAPA) was able to alleviate the effects of fbxo22 deletion on colorectal inflammatory response and CRC. These RAPA effects are correlated with the ability of RAPA to inhibit pS2448-mTOR, pS6K1, and p4E-BP1. Collectively, our data support a suppressive role for FBXO22 in colorectal inflammation signaling and CRC initiation by targeting pS2448-mTOR for degradation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TOR Serine-Threonine KinasesColorectal NeoplasmsColitisF-Box ProteinsMice, KnockoutAnimalsMiceHumansPhosphorylationProteolysisAzoxymethaneCarcinogenesisDextran SulfateReceptors, Cytoplasmic and Nuclear

Stichwörter der Autor:innen

FBXO22colitiscolorectal carcinogenesispS2448-mTOR

Substanzen

TOR Serine-Threonine KinasesF-Box ProteinsmTOR protein, mouseAzoxymethaneFBXO22 protein, humanMTOR protein, humanDextran SulfateReceptors, Cytoplasmic and Nuclear

Autor:innen und Institutionen

  • Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
  • Department of Gastroenterology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
  • Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 211166,…
  • Center of Clinical Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
  • Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
  • Department of Oncological Sciences, The Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574.

ORCID-Profile: Jin Bai

Förderung

  • NCI NIH HHS

Zitieren

APA

Li, M., Chen, X., Qu, P., Shao, Z., Shi, L., Quan, H., Zhao, X., Xu, J., Shi, L., Chen, S., Zheng, J., Pan, Z. Q., & Bai, J. (2024). FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2402035121

Vancouver

Li M, Chen X, Qu P, Shao Z, Shi L, Quan H, et al. FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2402035121

BibTeX
@article{Li2024,
  author = {Li, Minle and Chen, Xuan and Qu, Pengfei and Shao, Zhiying and Shi, Lei and Quan, Haoyu and Zhao, Xue and Xu, Jian and Shi, Luling and Chen, Silu and Zheng, Junnian and Pan, Zhen-Qiang and Bai, Jin},
  title = {FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2402035121}
}
Kostenlos starten →